Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.23
NKTR's Cash to Debt is ranked lower than
71% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. NKTR: 2.23 )
Ranked among companies with meaningful Cash to Debt only.
NKTR' s 10-Year Cash to Debt Range
Min: 0.72  Med: 1.51 Max: 389.59
Current: 2.23
0.72
389.59
Equity to Asset 0.16
NKTR's Equity to Asset is ranked lower than
90% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NKTR: 0.16 )
Ranked among companies with meaningful Equity to Asset only.
NKTR' s 10-Year Equity to Asset Range
Min: -0.21  Med: 0.37 Max: 0.92
Current: 0.16
-0.21
0.92
F-Score: 6
Z-Score: -0.87
M-Score: -1.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 21.73
NKTR's Operating margin (%) is ranked higher than
88% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. NKTR: 21.73 )
Ranked among companies with meaningful Operating margin (%) only.
NKTR' s 10-Year Operating margin (%) Range
Min: -331.7  Med: -99.39 Max: -8.21
Current: 21.73
-331.7
-8.21
Net-margin (%) 9.01
NKTR's Net-margin (%) is ranked higher than
78% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. NKTR: 9.01 )
Ranked among companies with meaningful Net-margin (%) only.
NKTR' s 10-Year Net-margin (%) Range
Min: -322.72  Med: -100.88 Max: -12
Current: 9.01
-322.72
-12
ROE (%) 112.83
NKTR's ROE (%) is ranked higher than
99% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. NKTR: 112.83 )
Ranked among companies with meaningful ROE (%) only.
NKTR' s 10-Year ROE (%) Range
Min: -140.39  Med: -39.31 Max: -14.84
Current: 112.83
-140.39
-14.84
ROA (%) 5.48
NKTR's ROA (%) is ranked higher than
84% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. NKTR: 5.48 )
Ranked among companies with meaningful ROA (%) only.
NKTR' s 10-Year ROA (%) Range
Min: -38.56  Med: -18.05 Max: -4.39
Current: 5.48
-38.56
-4.39
ROC (Joel Greenblatt) (%) 88.46
NKTR's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. NKTR: 88.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NKTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -203.29  Med: -75.89 Max: -9.76
Current: 88.46
-203.29
-9.76
Revenue Growth (3Y)(%) 35.90
NKTR's Revenue Growth (3Y)(%) is ranked higher than
87% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. NKTR: 35.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NKTR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -31.4  Med: 8.40 Max: 59.6
Current: 35.9
-31.4
59.6
EBITDA Growth (3Y)(%) -72.40
NKTR's EBITDA Growth (3Y)(%) is ranked lower than
98% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. NKTR: -72.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NKTR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -72.4  Med: 14.50 Max: 108
Current: -72.4
-72.4
108
EPS Growth (3Y)(%) -29.30
NKTR's EPS Growth (3Y)(%) is ranked lower than
77% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. NKTR: -29.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NKTR' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.4  Med: 10.60 Max: 101
Current: -29.3
-44.4
101
» NKTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NKTR Guru Trades in Q2 2014

PRIMECAP Management 15,804,286 sh (+1.74%)
» More
Q3 2014

NKTR Guru Trades in Q3 2014

PRIMECAP Management 18,137,786 sh (+14.76%)
» More
Q4 2014

NKTR Guru Trades in Q4 2014

Stanley Druckenmiller 655,000 sh (New)
Jim Simons 432,148 sh (New)
Paul Tudor Jones 11,698 sh (New)
PRIMECAP Management 18,225,786 sh (+0.49%)
» More
Q1 2015

NKTR Guru Trades in Q1 2015

Jim Simons 568,048 sh (+31.45%)
PRIMECAP Management 19,552,586 sh (+7.28%)
Stanley Druckenmiller 655,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NKTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 69.68
NKTR's P/E(ttm) is ranked lower than
72% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. NKTR: 69.68 )
Ranked among companies with meaningful P/E(ttm) only.
NKTR' s 10-Year P/E(ttm) Range
Min: 64.49  Med: 70.00 Max: 83.17
Current: 69.68
64.49
83.17
Forward P/E 22.52
NKTR's Forward P/E is ranked higher than
55% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. NKTR: 22.52 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 75.20
NKTR's PE(NRI) is ranked lower than
72% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. NKTR: 75.20 )
Ranked among companies with meaningful PE(NRI) only.
NKTR' s 10-Year PE(NRI) Range
Min: 63.35  Med: 68.76 Max: 81.71
Current: 75.2
63.35
81.71
P/B 19.73
NKTR's P/B is ranked lower than
92% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. NKTR: 19.73 )
Ranked among companies with meaningful P/B only.
NKTR' s 10-Year P/B Range
Min: 1.97  Med: 5.09 Max: 58
Current: 19.73
1.97
58
P/S 5.40
NKTR's P/S is ranked higher than
70% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. NKTR: 5.40 )
Ranked among companies with meaningful P/S only.
NKTR' s 10-Year P/S Range
Min: 1.76  Med: 9.18 Max: 16.68
Current: 5.4
1.76
16.68
EV-to-EBIT 21.36
NKTR's EV-to-EBIT is ranked higher than
64% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. NKTR: 21.36 )
Ranked among companies with meaningful EV-to-EBIT only.
NKTR' s 10-Year EV-to-EBIT Range
Min: -140.8  Med: -8.50 Max: 27.2
Current: 21.36
-140.8
27.2
Current Ratio 4.60
NKTR's Current Ratio is ranked higher than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. NKTR: 4.60 )
Ranked among companies with meaningful Current Ratio only.
NKTR' s 10-Year Current Ratio Range
Min: 1  Med: 6.04 Max: 16.32
Current: 4.6
1
16.32
Quick Ratio 4.44
NKTR's Quick Ratio is ranked higher than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. NKTR: 4.44 )
Ranked among companies with meaningful Quick Ratio only.
NKTR' s 10-Year Quick Ratio Range
Min: 0.96  Med: 5.94 Max: 16.32
Current: 4.44
0.96
16.32
Days Inventory 161.07
NKTR's Days Inventory is ranked lower than
65% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. NKTR: 161.07 )
Ranked among companies with meaningful Days Inventory only.
NKTR' s 10-Year Days Inventory Range
Min: 33.21  Med: 158.21 Max: 247.21
Current: 161.07
33.21
247.21
Days Sales Outstanding 3.63
NKTR's Days Sales Outstanding is ranked higher than
95% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. NKTR: 3.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
NKTR' s 10-Year Days Sales Outstanding Range
Min: 5.46  Med: 24.79 Max: 79.04
Current: 3.63
5.46
79.04

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1217.00
NKTR's Price/Tangible Book is ranked lower than
100% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. NKTR: 1217.00 )
Ranked among companies with meaningful Price/Tangible Book only.
NKTR' s 10-Year Price/Tangible Book Range
Min: 3.55  Med: 6.36 Max: 1100
Current: 1217
3.55
1100
Price/Median PS Value 0.61
NKTR's Price/Median PS Value is ranked higher than
81% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. NKTR: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
NKTR' s 10-Year Price/Median PS Value Range
Min: 0.21  Med: 1.17 Max: 4.65
Current: 0.61
0.21
4.65
Price/Graham Number 71.59
NKTR's Price/Graham Number is ranked lower than
98% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.52 vs. NKTR: 71.59 )
Ranked among companies with meaningful Price/Graham Number only.
NKTR' s 10-Year Price/Graham Number Range
Min: 64.71  Med: 64.71 Max: 64.71
Current: 71.59
Earnings Yield (Greenblatt) (%) 4.67
NKTR's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. NKTR: 4.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NKTR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.7  Med: 4.50 Max: 4.9
Current: 4.67
3.7
4.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ITH.Germany,
Nektar Therapeutics Inc was incorporated in July 1990 and reincorporated in Delaware in 1998. The Company is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its current proprietary pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. The Company creates its drug candidates by using its proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of drugs to create new molecular entities. The Company's drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its proprietary drug candidate, NKTR-118, is an oral peripherally-acting opioid antagonist, currently in Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain. OIC is a common side effect of prescription opioids when used for chronic pain management. In September 2009, the Company entered into a global license agreement with AstraZeneca AB for the development and commercialization of NKTR-118 and NKTR-119. NKTR-119 is an early stage research and development program that is designed to combine various opioids with NKTR-118. AstraZeneca is responsible for all clinical, regulatory and commercialization costs for NKTR-118 and NKTR-119. The Company has several proprietary pre-clinical and clinical drug candidates that are in the pain therapeutic area. NKTR-181 is an orally-available mu-opioid analgesic molecule with a long-acting profile to treat chronic pain that has been designed with the objective of addressing serious CNS-related side effects associated with standard opioid therapies. The Company also has a collaboration with Bayer Healthcare LLC "Bayer" to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic. Bayer has initiated a Phase 3 clinical development of BAY41-6551 with the first patient enrolled in April 2013. The Company frequently competes with pharmaceutical companies and other institutions. As a manufacturer of PEG reagents for the U.S. market, the Company is subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time.
» More Articles for NKTR

Headlines

Articles On GuruFocus.com
Weekly Guru Bargains Highlights: AKAM, NKTR, LOGI, FFIV, LCC Apr 16 2011 
Weekly Guru Bargains Highlights: AMSC, LOGI, NKTR, DAL, AIG Apr 09 2011 
Four Guru Stocks near New Lows: FBN, HOME, NKTR, PETS Feb 07 2011 
MannKind: Deja Vu for the FDA and Afrezza Dec 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 04 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Jul 29 2010 
Nektar Therapeutics Reports Operating Results (10-Q) May 06 2010 
cooldecency99 note on NKTR May 01 2010 
Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year Jan 06 2010 
Nektar Therapeutics Reports Operating Results (10-Q) Nov 05 2009 

More From Other Websites
Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After... Jul 29 2015
Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After... Jul 29 2015
Baxalta & Nektar Reveal Full Data from Hemophilia Study - Analyst Blog Jul 17 2015
NEKTAR THERAPEUTICS Files SEC form 8-K, Other Events Jul 16 2015
Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention... Jul 16 2015
Mid-Morning Market Update: Markets Open Lower; Lennar Beats Q2 Estimates Jun 24 2015
Columbia Pipeline to Join the S&P 500; Other Changes to S&P MidCap 400 & S&P SmallCap 600 Jun 24 2015
Biotech bargain bin Jun 19 2015
NEKTAR THERAPEUTICS Files SEC form 8-K, Change in Directors or Principal Officers, Submission of... Jun 17 2015
Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for... Jun 02 2015
Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for... Jun 02 2015
bluebird bio Inc (BLUE), Nektar Therapeutics (NKTR) Among Billionaire Stan Druckenmiller’s Top... May 28 2015
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2015 Global... May 28 2015
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2015 Global... May 28 2015
Biotech Fans Could Have a Hangover May 14 2015
Nektar Swings to Q1 Earnings, Updates 2015 Guidance - Analyst Blog May 04 2015
10-Q for Nektar Therapeutics May 03 2015
NEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report May 01 2015
Nektar tops Street 1Q forecasts Apr 30 2015
Nektar tops Street 1Q forecasts Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK